ShigellosisPhase 1NCT05959616
Shigella Sonnei 53G Human Infection Study in Kenyan Adults
A Phase 1 study testing Shigella sonnei 53G and Ciprofloxacin 500 mg in people with Shigellosis, run by University of Oxford at 1 site in Kenya.
Trial summary
Diarrhoea caused by Shigella (shigellosis) is of major public health importance. However, there are no licensed Shigella vaccines in routine use, with several candidates still in various stages of clinical development. Shigella human infection studies (HIS) have played a key role in vaccine development. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Shigellosis
- What is being tested?
- Shigella sonnei 53G and Ciprofloxacin 500 mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteKenya
- Study dates
- 21 Jan 2025to 30 Aug 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy adults between 18 and 45 years of age (inclusive) Kilifi County residents
- Able and willing (in the Investigator's opinion) to comply with all study requirements.
- Provide informed consent.
- Demonstrate comprehension of the protocol procedures and knowledge of study by passing a test of understanding (pass grade 100%).
- Use of effective method of contraception for the entire duration of study (prior to study start and up to study completion) (women only). Female volunteers will be asked to provide their family planning records to verify. Effective contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly, in accordance with the product label. Examples of these include: combined oral contraceptives; injectable progestogen; implants of etenogestrel or levonorgestrel; intrauterine device or intrauterine system; male partner sterilisation at least 6 months prior to the female volunteer's entry into the study, and the relationship is monogamous; male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository); and male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository).
- Willingness to participate for an inpatient stay lasting approximately 12 days or longer and an outpatient follow-up lasting about 12 months from challenge.
- Available for all planned follow-up visits.
Who cannot join
- Presence of a significant medical condition (e.g., psychiatric conditions, alcohol or illicit drug abuse/dependency, or gastrointestinal disease, such as peptic ulcer, symptoms or evidence of active gastritis or gastroesophageal reflux disease, inflammatory bowel disease), or other laboratory abnormalities which in the opinion of the investigator precludes participation in the study.
- Known immunosuppressive illness for example those with cancer, on immunosuppressive therapy, HIV etc.
- Positive serology results for HIV, HBsAg, or HCV antibodies.
- Evidence of inflammatory arthritis on exam and/or HLA-B27 positive.
- Family history of inflammatory arthritis.
- Clinically significant abnormalities in screening lab haematology or serum chemistry, as determined by PI or PI in consultation with the research monitor and Sponsor.
Show all 25Show fewer
- Known allergies to fluoroquinolones, β-lactams or trimethoprim-sulfamethoxazole (any of the three are exclusionary).
- Fewer than 3 stools per week or more than 3 stools per day as the usual frequency.
- History of diarrhoea in the 2 weeks prior to planned inpatient phase.
- Use of antibiotics during the 7 days before receiving the challenge inoculum dosing.
- Use of prescription and/or OTC medications that contain imodium, acetaminophen, aspirin, ibuprofen, and/or other non-steroidal anti-inflammatory drugs, during the 48 hours prior to investigational product administration.
- Confirmed PCR positive for SARS-COV-2 three days before challenge i.e., Day -3.
- Use of any medication known to affect the immune function within 30 days preceding receipt of the challenge inoculum or planned use during the active study period.
- Serologic evidence of prior S. sonnei infection as determined by ELISA.
- A chronic disease for which doses of prescription medications are not stable for at least the past 3 months.
- Have known immunocompromised household contacts for example those with cancer, on immunosuppressive therapy, HIV etc.
- A clinically significant abnormality on physical examination, including a systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg, or a resting pulse >100 beats/min or <55 beats/min (<50 beats/min for conditioned athletes).
- Pregnant, nursing, or planning to become pregnant within 29 days of receipt of the study product.
- In the 4 weeks following challenge, volunteer will be living with or having daily contact with elderly persons aged 70 years or more, diapered individuals, persons with disabilities, children <2 years old, a woman known to be pregnant or nursing, or anyone with diminished immunity. This includes contact at work, home, school, day-care, nursing homes, or similar places.
- Work in a health care setting, day care center, or as a food handler in the 4 weeks following the challenge with S. sonnei.
- Use of any investigational drug or any investigational vaccine within 60 days preceding challenge, or planned use during the 6 months after receipt of the study agent.
- Have received a licensed, live vaccine within 28 days or a licensed inactivated vaccine within 14 days of receiving the challenge inoculum.
- Inability to comply with inpatient rules and regulations.
- Has any other condition that, in the opinion of the Investigator, would jeopardize the safety or rights of a volunteer (e.g., infection with another detected pathogen) or would render the volunteer unable to comply with the protocol.
- Received blood or blood products within the past six months.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Kenya1 site, 1 recruiting
- Recruiting
KEMRI-Wellcome Trust Research Programme
Kilifi, 80108
Melissa Kapulu, PhD, +254709983463, mkapulu@kemri-wellcome.org
Mainga Hamaluba, MD, +254709983946
About this study
Official title: Safety and Feasibility of a Shigella Sonnei 53G Controlled Human Infection Model in Kenyan Adults: a Dose Finding and Dose Verification Study
Diarrhoea caused by Shigella (shigellosis) is of major public health importance. However, there are no licensed Shigella vaccines in routine use, with several candidates still in various stages of clinical development. Shigella human infection studies (HIS) have played a key role in vaccine development. These models also allow for the evaluation of immunity and other non-immunological parameters that are important to understand resistance and/or susceptibility to disease. This is particularly useful in individuals from endemic areas with varying levels of prior exposure and immunity to Shigella. Thus, establishing a Shigella HIS would enable the testing of interventions such as vaccines in a population that would most benefit from a subsequent vaccine and has potential to accelerate vaccine development. Here, the goal is to successfully establish a Shigella sonnei human infection model in Kenyan adults. This will be achieved by conducting dose-finding and dose verification Shigella studies that safely and reproducibly induce ≥60% attack rates. In this study, investigators aim to use Shigella HIS in healthy adults to develop a model as a platform to test vaccines, to study immune responses identifying potential correlates of infection, and non-immunological factors mediating and influencing susceptibility to disease. To achieve this, the study will be carried out in two phases over a period of 12-14 months. Phase A will enroll (N=up to 40 volunteers) and Phase B will enroll an additional (N=30 volunteers). To be eligible to receive a dose of 53G, volunteers must pass the screening visit. Investigators will vary the dose of bacteria in individuals enrolled for challenge to identify the dose needed to cause ≥60% shigellosis (attack rate) (Phase A) followed by testing and demonstrate the reproducibility of the model (Phase B). Thus, the main outcomes of the study will be: (1) optimisation of bacterial dose for infection success (≥60% attack rate); and (2) safety.
Read the detailed description
This is a Phase 1 dose finding and dose verification study which will be used to determine the dose of S. sonnei 53G that induces the primary outcome in approximately ≥60% of Kenyan adult volunteers. This study will occur in two phases, Phase A (dose-finding) with up to 40 volunteers challenged with 53G and Phase B (dose verification) with N=30 volunteers planned to be administered 53G. Based on previously published data using this model, 1,500 colony-forming units (CFU) will be the dose administered to the first cohort. Dosing of subsequent cohorts will depend on results of the previous cohort. If a lower-than-expected attack rate (AR) occurs, the dose for the next cohort will be increased by 500 CFU. Conversely, if the AR is higher than expected the dose for the next cohort will be decreased by 500 CFU. Cohorts of volunteers will continue to be challenged until either; a dose that reproducibly causes infection in at least 60% of volunteers; safety precludes continuing (>90% AR at 500 CFU) or futility (an AR of 60% is unable to be achieved, even with a 3000 CFU dose). It may take more or less than 3 dose-finding groups to find the optimal dose for which the primary outcome (shigellosis) is achieved in approximately ≥60% of the volunteers and thus the total number of volunteers enrolled in both phases may be less or more than N=60. Once the optimal dose is established in Phase A, that dose will be carried forward for verification in Phase B. For Phase B, dose verification groups of 30 volunteers (2 cohorts of 15 volunteers per cohort) will be conducted to verify the AR with the chosen dose. The dose finding and verification stages will be done in a staggered fashion in case the dose needs to be adjusted, resulting in approximately 5 cohorts to be enrolled over time. Allocation into the groups will be on "first come first served basis" with no randomization occurring for enrolment in any of the cohorts.
- Conditions
- Shigellosis
- Being tested
- Shigella sonnei 53G, Ciprofloxacin 500 mg
- Medical subject headings
- Dysentery, Bacillary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Shigella sonnei 53GBiological
Lyophilized S. sonnei 53G strain (Lot 1794)
Ciprofloxacin 500 mgDrug
Ciprofloxacin (500 mg orally twice daily for three days),
| Study group | Role | What they receive |
|---|---|---|
| Group 1 Shigella sonnei 53G 1500CFU (N=10) | Experimental | Dose finding group
Group 1 will receive lyophilised S. sonnei 53G strain at a dose of 1500CFU.
Group 1 will receive curative treatment of Ciprofloxacin. Receives: Biological: Shigella sonnei 53G; Drug: Ciprofloxacin 500 mg |
| Group 2 Shigella sonnei 53G 2000CFU (N=10) | Experimental | Dose finding group
Group 2 will receive lyophilised S. sonnei 53G strain at a dose of 2000CFU.
Group 2 will receive curative treatment of Ciprofloxacin. Receives: Biological: Shigella sonnei 53G; Drug: Ciprofloxacin 500 mg |
| Group 3 Shigella sonnei 53G 2500CFU (N=10) | Experimental | Dose finding group
Group 3 will receive lyophilised S. sonnei 53G strain at a dose of 2500CFU.
Group 3 will receive curative treatment of Ciprofloxacin. Receives: Biological: Shigella sonnei 53G; Drug: Ciprofloxacin 500 mg |
| Group 4 Shigella sonnei 53G 3000CFU (N=10) | Experimental | Dose finding group
Group 4 will receive lyophilised S. sonnei 53G strain at a dose of 3000CFU.
Group 4 will receive curative treatment of Ciprofloxacin. Receives: Biological: Shigella sonnei 53G; Drug: Ciprofloxacin 500 mg |
| Group 5 Shigella sonnei 53G TBDCFU (N=15) | Experimental | Dose verification group
Group 5 will receive lyophilised S. sonnei 53G strain at a dose TBD.
Group 5 will receive curative treatment of Ciprofloxacin. Receives: Biological: Shigella sonnei 53G; Drug: Ciprofloxacin 500 mg |
| Group 6 Shigella sonnei 53G TBDCFU (N=15) | Experimental | Dose verification group
Group 6 will receive lyophilised S. sonnei 53G strain at a dose TBD.
Group 6 will receive curative treatment of Ciprofloxacin. Receives: Biological: Shigella sonnei 53G; Drug: Ciprofloxacin 500 mg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of volunteers with solicited adverse events
Occurrence and severity of solicited adverse events (AEs) through 11 days post-challenge. Occurrence, severity, and relatedness of unsolicited AEs through 11 days post-challenge. Occurrence, severity, and relatedness of serious adverse events (SAEs) throughout the entire study. Occurrence of abnormal clinical laboratory values within 11 days post challenge. Percent of volunteers with nausea, vomiting, anorexia, abdominal pain/cramps rated as moderate to severe.
Measured: Through 11 days post challenge
Number of volunteers with an attack rate of ≥60%
Confirmation of the dose with an acceptable safety profile as determined by that gives an attack rate of ≥60% of shigellosis in Kenyan adults.
Measured: Through 11 days post challenge
Secondary outcomes (3)
Percent of volunteers with
Maximum 24-hour stool output
Measured: Through 11 days post challenge
Percent of volunteers shedding
Peak shedding levels of the 53G challenge strain (CFUs/g of stool) post-challenge based on the results of quantitative cultures post-challenge
Measured: Through 11 days post challenge
Kinetics of serum IgA and IgG antibody responses
- sonnei O-Ag, LPS, IpaB, and IpaC;
Measured: From baseline to 366 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jul 2023
- Study start21 Jan 2025
- Primary completion30 Apr 2026 (estimated)
- Study completion30 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ShigellosisStudies of the same condition, open and under way.
- More trials run by University of OxfordThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Oxford
- Sponsor type
- University, hospital or other
- Collaborators
- KEMRI-Wellcome Trust Collaborative Research Program, KEMRI United States Army Medical Research Directorate-Kenya, Walter Reed Army Institute of Research (WRAIR), Naval Medical Research Center, PATH, Johns Hopkins University
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05959616
- Sponsor's protocol ID
- OxTREC27-22
- Status last verified
- May 2024
- First submitted
- 29 Jun 2023
- Last updated
- 13 Mar 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Within 2 years of the study completion date
Study at a glance
From the registry record, last updated by the sponsor on 13 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety and Feasibility of a Shigella Sonnei 53G Controlled Human Infection Model in Kenyan Adults: a Dose Finding and Dose Verification Study
- ClinicalTrials.gov ID
- NCT05959616
- Acronym / sponsor ID
- OxTREC27-22
- Conditions
- Shigellosis
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- University of OxfordUniversity, hospital or other
- Collaborators
- KEMRI-Wellcome Trust Collaborative Research Program, KEMRI United States Army Medical Research Directorate-Kenya, Walter Reed Army Institute of Research (WRAIR), Naval Medical Research Center, PATH, Johns Hopkins University
- Study start
- 21 Jan 2025 (actual)
- Primary completion
- 30 Apr 2026 (estimated)
- Study completion
- 30 Aug 2027 (estimated)
- First posted
- 25 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Diarrhoea caused by Shigella (shigellosis) is of major public health importance. However, there are no licensed Shigella vaccines in routine use, with several candidates still in various stages of clinical development. Shigella human infection studies (HIS) have played a key role in vaccine development. These models also allow for the evaluation of immunity and other non-immunological parameters that are important to understand resistance and/or susceptibility to disease. This is particularly useful in individuals from endemic areas with varying levels of prior exposure and immunity to Shigella. Thus, establishing a Shigella HIS would enable the testing of interventions such as vaccines in a population that would most benefit from a subsequent vaccine and has potential to accelerate vaccine development. Here, the goal is to successfully establish a Shigella sonnei human infection model in Kenyan adults. This will be achieved by conducting dose-finding and dose verification Shigella studies that safely and reproducibly induce ≥60% attack rates. In this study, investigators aim to use Shigella HIS in healthy adults to develop a model as a platform to test vaccines, to study immune responses identifying potential correlates of infection, and non-immunological factors mediating and influencing susceptibility to disease. To achieve this, the study will be carried out in two phases over a period of 12-14 months. Phase A will enroll (N=up to 40 volunteers) and Phase B will enroll an additional (N=30 volunteers). To be eligible to receive a dose of 53G, volunteers must pass the screening visit. Investigators will vary the dose of bacteria in individuals enrolled for challenge to identify the dose needed to cause ≥60% shigellosis (attack rate) (Phase A) followed by testing and demonstrate the reproducibility of the model (Phase B). Thus, the main outcomes of the study will be: (1) optimisation of bacterial dose for infection success (≥60% attack rate); and (2) safety.
Detailed description
This is a Phase 1 dose finding and dose verification study which will be used to determine the dose of S. sonnei 53G that induces the primary outcome in approximately ≥60% of Kenyan adult volunteers. This study will occur in two phases, Phase A (dose-finding) with up to 40 volunteers challenged with 53G and Phase B (dose verification) with N=30 volunteers planned to be administered 53G. Based on previously published data using this model, 1,500 colony-forming units (CFU) will be the dose administered to the first cohort. Dosing of subsequent cohorts will depend on results of the previous cohort. If a lower-than-expected attack rate (AR) occurs, the dose for the next cohort will be increased by 500 CFU. Conversely, if the AR is higher than expected the dose for the next cohort will be decreased by 500 CFU. Cohorts of volunteers will continue to be challenged until either; a dose that reproducibly causes infection in at least 60% of volunteers; safety precludes continuing (>90% AR at 500 CFU) or futility (an AR of 60% is unable to be achieved, even with a 3000 CFU dose). It may take more or less than 3 dose-finding groups to find the optimal dose for which the primary outcome (shigellosis) is achieved in approximately ≥60% of the volunteers and thus the total number of volunteers enrolled in both phases may be less or more than N=60. Once the optimal dose is established in Phase A, that dose will be carried forward for verification in Phase B. For Phase B, dose verification groups of 30 volunteers (2 cohorts of 15 volunteers per cohort) will be conducted to verify the AR with the chosen dose. The dose finding and verification stages will be done in a staggered fashion in case the dose needs to be adjusted, resulting in approximately 5 cohorts to be enrolled over time. Allocation into the groups will be on "first come first served basis" with no randomization occurring for enrolment in any of the cohorts.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Group 1 Shigella sonnei 53G 1500CFU (N=10) | Experimental | Biological: Shigella sonnei 53G, Drug: Ciprofloxacin 500 mgDose finding group Group 1 will receive lyophilised S. sonnei 53G strain at a dose of 1500CFU. Group 1 will receive curative treatment of Ciprofloxacin. |
| Group 2 Shigella sonnei 53G 2000CFU (N=10) | Experimental | Biological: Shigella sonnei 53G, Drug: Ciprofloxacin 500 mgDose finding group Group 2 will receive lyophilised S. sonnei 53G strain at a dose of 2000CFU. Group 2 will receive curative treatment of Ciprofloxacin. |
| Group 3 Shigella sonnei 53G 2500CFU (N=10) | Experimental | Biological: Shigella sonnei 53G, Drug: Ciprofloxacin 500 mgDose finding group Group 3 will receive lyophilised S. sonnei 53G strain at a dose of 2500CFU. Group 3 will receive curative treatment of Ciprofloxacin. |
| Group 4 Shigella sonnei 53G 3000CFU (N=10) | Experimental | Biological: Shigella sonnei 53G, Drug: Ciprofloxacin 500 mgDose finding group Group 4 will receive lyophilised S. sonnei 53G strain at a dose of 3000CFU. Group 4 will receive curative treatment of Ciprofloxacin. |
| Group 5 Shigella sonnei 53G TBDCFU (N=15) | Experimental | Biological: Shigella sonnei 53G, Drug: Ciprofloxacin 500 mgDose verification group Group 5 will receive lyophilised S. sonnei 53G strain at a dose TBD. Group 5 will receive curative treatment of Ciprofloxacin. |
| Group 6 Shigella sonnei 53G TBDCFU (N=15) | Experimental | Biological: Shigella sonnei 53G, Drug: Ciprofloxacin 500 mgDose verification group Group 6 will receive lyophilised S. sonnei 53G strain at a dose TBD. Group 6 will receive curative treatment of Ciprofloxacin. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Healthy adults between 18 and 45 years of age (inclusive) Kilifi County residents
- Able and willing (in the Investigator's opinion) to comply with all study requirements.
- Provide informed consent.
- Demonstrate comprehension of the protocol procedures and knowledge of study by passing a test of understanding (pass grade 100%).
- Use of effective method of contraception for the entire duration of study (prior to study start and up to study completion) (women only). Female volunteers will be asked to provide their family planning records to verify. Effective contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly, in accordance with the product label. Examples of these include: combined oral contraceptives; injectable progestogen; implants of etenogestrel or levonorgestrel; intrauterine device or intrauterine system; male partner sterilisation at least 6 months prior to the female volunteer's entry into the study, and the relationship is monogamous; male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository); and male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository).
Key exclusion criteria (25 listed)
- Presence of a significant medical condition (e.g., psychiatric conditions, alcohol or illicit drug abuse/dependency, or gastrointestinal disease, such as peptic ulcer, symptoms or evidence of active gastritis or gastroesophageal reflux disease, inflammatory bowel disease), or other laboratory abnormalities which in the opinion of the investigator precludes participation in the study.
- Known immunosuppressive illness for example those with cancer, on immunosuppressive therapy, HIV etc.
- Positive serology results for HIV, HBsAg, or HCV antibodies.
- Evidence of inflammatory arthritis on exam and/or HLA-B27 positive.
- Family history of inflammatory arthritis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Shigella sonnei 53GLyophilized S. sonnei 53G strain (Lot 1794) | Biological | Group 1 Shigella sonnei 53G 1500CFU (N=10), Group 2 Shigella sonnei 53G 2000CFU (N=10), Group 3 Shigella sonnei 53G 2500CFU (N=10), Group 4 Shigella sonnei 53G 3000CFU (N=10), Group 5 Shigella sonnei 53G TBDCFU (N=15), Group 6 Shigella sonnei 53G TBDCFU (N=15) |
| Ciprofloxacin 500 mgCiprofloxacin (500 mg orally twice daily for three days), | Drug | Group 1 Shigella sonnei 53G 1500CFU (N=10), Group 2 Shigella sonnei 53G 2000CFU (N=10), Group 3 Shigella sonnei 53G 2500CFU (N=10), Group 4 Shigella sonnei 53G 3000CFU (N=10), Group 5 Shigella sonnei 53G TBDCFU (N=15), Group 6 Shigella sonnei 53G TBDCFU (N=15) |
Primary outcome
Number of volunteers with solicited adverse events
Time frame: Through 11 days post challenge
Occurrence and severity of solicited adverse events (AEs) through 11 days post-challenge. Occurrence, severity, and relatedness of unsolicited AEs through 11 days post-challenge. Occurrence, severity, and relatedness of serious adverse events (SAEs) throughout the entire study. Occurrence of abnormal clinical laboratory values within 11 days post challenge. Percent of volunteers with nausea, vomiting, anorexia, abdominal pain/cramps rated as moderate to severe.
Number of volunteers with an attack rate of ≥60%
Time frame: Through 11 days post challenge
Confirmation of the dose with an acceptable safety profile as determined by that gives an attack rate of ≥60% of shigellosis in Kenyan adults.
3 secondary outcomes
Percent of volunteers with
Time frame: Through 11 days post challenge
Percent of volunteers shedding
Time frame: Through 11 days post challenge
Kinetics of serum IgA and IgG antibody responses
Time frame: From baseline to 366 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Mar 2025.
- Individual participant dataSharing planned: Yes. Within 2 years of the study completion date
Related trials for Shigellosis
RecruitingPhase 2
Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children
Diarrhoea
Not yet recruitingPhase 1/2
Safety and Immunogenicity Study of IP-QSV Vaccine in Healthy Adults/Adolescents, Children and Infants
Shigella Infection
Active, not recruitingPhase 3
Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjugate Vaccine
Dysentery, Dysentery, Shigella
RecruitingPhase 2
The Impact of Shigellosis and Recommended Treatment in Children
Diarrhea Infectious, Shigella
RecruitingPhase 1
First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults
Shigella, Diarrhea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Shigella sonnei 53G and Ciprofloxacin 500 mg in people with Shigellosis, run by University of Oxford at 1 site in Kenya.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Kenya. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of volunteers with solicited adverse events (time frame: Through 11 days post challenge). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2025.